Isoniazid
This first-line antibiotic is used to treat and prevent tuberculosis (TB) by inhibiting mycolic acid synthesis, a key component of the mycobacterial cell wall. It is one of the most important TB drugs and is used in combination with other agents to prevent the development of resistance. Long-term use requires supplementation with vitamin B6 (pyridoxine) to prevent peripheral neuropathy.
Molekularmasse
137,1400 g/mol
LogP
-0,70
TPSA
68,00 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
2D-Struktur
Cite this structure
Embed this structure
SMILES
NNC(=O)c1ccncc1
InChI
InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
Molecular Formula
C6H7N3O
HBD / HBA
2 / 3
Rotierbare Bindungen
1
Schwere Atome
10
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This first-line antibiotic is used to treat and prevent tuberculosis (TB) by inhibiting mycolic acid synthesis, a key component of the mycobacterial cell wall. It is one of the most important TB drugs and is used in combination with other agents to prevent the development of resistance. Long-term use requires supplementation with vitamin B6 (pyridoxine) to prevent peripheral neuropathy.
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Yes, Isoniazid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL64. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3767. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="isoniazid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/isoniazid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/isoniazid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/isoniazid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="isoniazid"></drugfyi-drug>